Conagra Brands Inc. (NYSE: CAG) is scheduled to report second quarter 2020 earnings results on Thursday, December 19, before the market opens. Analysts have projected earnings of $0.57 per share on revenue of $2.8 billion.
The quarterly results are likely to benefit from strength in the portfolio as well as innovations within the snacks and frozen businesses. Last quarter, the topline benefited from the Pinnacle acquisition. The company previously said that the investments being made in the first half, particularly the second quarter, will drive strong second half performance.
During the quarter, Conagra completed the divestiture of its DSD model snacks business to Utz Quality Foods. The company had earlier said it estimated the deal to reduce sales by about $110 million and adjusted EPS by $0.02 annually post-closing. Updates on this transaction are worth watching. Higher input costs along with expenses related to growth investments are likely to weigh on margins.
In the first quarter of 2020, Conagra beat earnings estimates while sales fell short of expectations. Sales rose 30% to $2.39 billion while adjusted EPS dropped nearly 9% to $0.43.
Also read: Conagra Q1 2020 Earnings Call Transcript
For fiscal year 2020, Conagra expects adjusted EPS to be $2.08 to $2.18, reported net sales to grow between 13.5% and 14.0% and organic net sales growth of 1.0% to 1.5%.
The company expects stronger organic net sales growth and adjusted EPS growth in the back half of fiscal 2020 than the first half due to the timing of the impact of new innovation, strong first-half brand-building investments that peak in the second quarter, the planned pace of synergy capture, and the lapping of both higher interest expense and share count.
Shares of Conagra have gained 35% year-to-date. The stock was up 1.6% in afternoon hours on Monday.
Most Popular
Intensity Therapeutics is establishing a new field of localized cancer reduction: CEO
Intensity Therapeutics, Inc. (NASDAQ: INTS) is a clinical biotechnology company engaged in the discovery development, and commercialization of first-in-class cancer drugs that attenuate tumors with minimal side effects while training
INTU Earnings: Intuit Q1 2025 adj. profit rises on higher revenues
Financial technology company Intuit Inc. (NASDAQ: INTU) Thursday announced results for the first quarter of 2025, reporting a modest increase in adjusted earnings. The Mountain View-headquartered company’s first-quarter revenue came
Riding the AI wave, Nvidia looks set to stay on the high-growth path
After delivering strong results for the third quarter, Nvidia Corporation (NASDAQ: NVDA) this week said the launch of its new-generation Blackwell chip is on track. The company is thriving on